Contemporary management of ST elevation myocardial infarction

Seminars in Thrombosis and Hemostasis

Volumn 30, Issue 6, 2004, Pages 673-681

  Weinstock, Barry S ^a,b  

^a Piedmont Hospital ^*  (United States)

^b PIEDMONT HOSPITAL   (United States)

Author keywords

Fibrinolytic agents; Fibrinolytic therapy; Glycoprotein IIb IIIa inhibitors; Myocardial infarction; PCI; Percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; RETEPLASE; STREPTOKINASE; TENECTEPLASE; TIROFIBAN;

BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY STENT; DRUG EFFICACY; FIBRINOLYTIC THERAPY; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH PROGRAM; HEART INFARCTION; HUMAN; META ANALYSIS; MORTALITY; OUTCOMES RESEARCH; PATIENT TRANSPORT; PERCUTANEOUS CORONARY INTERVENTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RECURRENT DISEASE; ST SEGMENT ELEVATION; SYSTEMATIC REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT PLANNING; VASCULAR PATENCY;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBOLYTIC THERAPY; TIME FACTORS;

EID: 11144304556     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-861510     Document Type: Conference Paper

References (32)

1. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO Investigators. N Engl J Med 1993;329:673-682
2. A comparison of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. N Engl J Med 1997;337:1118-1123
3. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomized trial. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators. Lancet 1999;354:716-722
4. Topol EJ. GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomized trial. Lancet 2001;357:1905-1914
5. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet 1986;1:397-402
6. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. The International Study Group. Lancet 1990;336:71-75
7. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988;2:349-360
8. Smalling RW, Bode C, Kalbfleischet J, et al. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation 1995;91:2725-2732
9. Bode C, Smalling RW, Berg G, et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation 1996;94:891-898
10. Gibson CM, Cannon CP, Murphy SA, et al. Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B Trial. Am J Cardiol 1999;84:976-980
11. Antman EM, Gibson CM, de Lemos JA, et al. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. Eur Heart J 2000;21:1944-1953
12. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Circulation 2000;101:2788-2794
13. Brener SJ, Zeymer U, Adgey A, et al. Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction The integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) Trial. J Am Coll Cardiol 2002;39:377-386
14. Giugliano RP, Roe M, Harrington R, et al. Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: Results of the Integrilin and Tenecteplase in Acute Myocardial Infarction (INTEGRITI) phase II angiographic Trial. J Am Coll Cardiol 2003;41:1251-1260
15. Weaver WD, Cerqueira M, Hallstrom AP, et al. Prehospital-initiated vs. hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial. JAMA 1993;270:1211-1216
16. Morrow DA, Antman EM, Sayah A, et al. Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infarction: results of the Early Retavase-Thrombolysis In Myocardial Infarction (ER-TIMI) 19 Trial. J Am Coll Cardiol 2002;40:71-77
17. American Heart Asociation 2002; Oral Presentation and www.clinicaltrialresults.org
18. de Bono DP. The European Cooperative Study Group trial of intravenous recombinant tissue-type plasminogen activator (rt-PA) and conservative therapy versus rt-PA and immediate coronary angioplasty. J Am Coll Cardiol 1988;12(6 Suppl A): 20A-23A
19. Topol EJ, Califf RM, Kereiakes DJ, George BS. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) trial. J Am Coll Cardiol 1987;10(5 Suppl B):65B-74B
20. O'Neill WW, Weintraub R, Grines CL, et al. A prospective, placebo-controlled, randomized trial of intravenous streptokinase and angioplasty versus lone angioplasty therapy of acute myocardial infarction. Circulation 1992;86:1710-1717
21. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993;328:673-679
22. Zijlstra F, de Boer MJ, Hoorntje J, et al. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993;328:680-684
23. Weaver WD, Simes RJ, Betriu A, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA 1997;278:2093-2098
24. Grines CL, Cox DA, Stone GW, et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. N Engl J Med 1999;341:1949-1956
25. Zhu MM, Feit A, Chadow H, et al. Primary stent implantation compared with primary balloon angioplasty for acute myocardial infarction: a meta-analysis of randomized clinical trials. Am J Cardiol 2001;88:297-301
26. Andersen HR. The Danish multicenter randomized trial on thrombolytic therapy versus acute coronary angioplasty in acute myocardial infarction. Presented at the American College of Cardiology's 51st Annual Scientific Session. Atlanta, GA; March 2002
27. Aversano T, Aversano LT, Passamani E, et al. Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery: a randomized controlled trial. JAMA 2002;287:1943-1951
28. Brener SJ, Barr LA, Burchenalet JE, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 1998;98:734-741
29. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-1903
30. Antionucci D. Abciximab carbostent evaluation. Presented at the TCT 14th Annual Symposium in Washington, D.C.; September 24-29, 2002
31. Kaul U, Gupta RK, Haridas KK, et al. Platelet glycoprotein IIb/IIIa inhibition using eptifibatide with primary coronary stenting for acute myocardial infarction: a 30-day follow-up study. Catheter Cardiovasc Interv 2002;57:497-503
32. Hermann HC, Moliterno DJ, Ohman EM, et al. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction. J Am Coll Cardiol 2000;36:1489-1496